| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Change Management > 2007 Change Management and Averting Chaos |
|
Advice You - 2007 Change Management and Averting Chaos
All things in life experience change and everywhere we look everywhere we go we observe change. We see th According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product e seasons change, the weather change, our bodies change and we experience events bringing about change. W ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in know that changes must be made in the heat of battle on the sports field during the game where new playe lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. rs are brought in and a transition is made for an upcoming defensive or offensive play. Change is often n here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe cessary, change is often forced and change is often the most favorable strategy to win. Everyone knows a d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro nd it is indeed no secret that anytime you change the human leadership on a sports team, government agenc ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc , non-profit group or business entity that there will be a short term transitional time that can cause sh easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ort-term disruption. The goal is for the smoothest possible transition of course while maintaining fluidi nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically y of motion on the field, in the battle space, in the market place or in the public’s eye. The sma and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ller the disruption and the smoother the transition the better for all concerned and this must be the goa ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi . Efficiency is paramount and the order of the day because when it comes to change there is no easy way. ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a apitalizing on change and discovering opportunity during the transition, minor chaos and disruption is of dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ten the key to successfully averting negative results and creating a winning situation. All is possible i cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin you focus on the game, mission and or marketplace. Embrace change and study the game to find opportunity tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen in chaos, while minimizing the affects and advancing the team. In this article I want you to consider t t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ese thoughts and discuss strategies of change in human leadership, the psychology of change, the primate ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust politics of organizations and case studies of how companies have dropped the ball during changes in upper y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products echelon executives and how other companies had found opportunity in the chaos of change. I very much appr . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de eciate you reading this article, as it is my first works on this topic for 2007 and yet something tells m elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip that it will not be my last and therefore. Perhaps this article is of interest to propel thought in 2007 tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Trucking Companies Can Survive With Freight Bill Factoring 2007 and The Power of Presence and Brand Marketing in the 21st Century
|